Maxim Group reaffirmed their hold rating on shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) in a research report sent to investors on Friday.

Separately, Zacks Investment Research raised Ritter Pharmaceuticals from a hold rating to a buy rating and set a $0.75 price target on the stock in a research note on Tuesday, May 23rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $5.21.

Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 0.60 on Friday. The firm has a 50-day moving average price of $0.58 and a 200 day moving average price of $1.53. Ritter Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.75. The firm’s market capitalization is $8.77 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.24. On average, analysts anticipate that Ritter Pharmaceuticals will post ($1.30) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. increased its stake in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. 13.95% of the stock is currently owned by hedge funds and other institutional investors.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.